NCT02435927Unknown1 期
Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
National Cancer Centre, Singapore1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2014年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD) of ASLAN001 when used in combination with Oxaliplatin and Capecitabine (CAPOX) or Oxaliplatin and 5-FU with leucovorin (mFolfox6)
研究概览
简要总结
This is a Phase I, open-label, dose escalation study of ASLAN001 given in combination with CAPOX or mFolfox6, in patients with metastatic solid tumours, whom are suitable to receive CAPOX or mFolfox6, or with tumours that have dysregulated EGFR or HER2 signaling.
详细描述
The study will use standard 3+3 design to determine the MTD (maximum tolerated dose) of ASLAN001 in combination with fixed dose of Oxaliplatin/Capecitabine (CAPOX) or 5-FU/leucovorin (mFolfox6).
MTD of ASLAN001 in combination with CAPOX will first be determined followed by the combination with mFolfox6.
The recommended Phase II dose will be the highest dose of the combination therapy that is considered to be tolerated in 6 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with metastatic solid tumours eligible for treatment with oxaliplatin in combination with capecitabine / 5-FU (fluorouracil) and leucovorin or who progressed following standard therapy or patients with EGFR (epidermal growth factor receptor ) or HER2 dysregulated tumours.
- •Patients with a partial gastrectomy may be allowed to participate in the study as long as they can take oral medications and meet all other inclusion/exclusion criteria.
- •Eastern Cooperative Oncology Group performance status of 0 or
- •Adequate organ and hematological function as evidenced by the following laboratory studies within 14 days prior to enrolment:
- •Hematological function, as follows: Absolute neutrophil count ≥ 1.5 x 109/L. Platelet count ≥ 100 x 109/L. Hemoglobin ≥ 9 g/dL.
- •Coagulation function, as follows: Prothrombin time and activated partial thromboplastin time ≤ 1.5 x upper limit of normal (ULN) per institutional laboratory normal range.
- •Renal function, as follows: Creatinine clearance ≥ 50 mL/min as calculated by Cockcroft-Gault formula.
- •Hepatic function, as follows: Total bilirubin ≤ 1.5 x ULN. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases are present).
- •Patients undergoing mandatory biopsy in dose expansion of a non-DLT cohort should have any of the following:
- •known HER2 or EGFR dysregulation
- •Patients with T790M mutation will be excluded.
- •Co-expression of HER2 and EGFR
- •Archival tumour sample is available for molecular profiling, unless undergoing tumour biopsy as part of the trial.
排除标准
- •Patients with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy.
- •Patients receiving proton pump inhibitors or H2 antagonists for established, symptomatic gastro duodenal ulceration or gastroesophageal reflux disease. H2 antagonist can be prescribed after DLT (dose-limiting toxicity) period (the first 2 cycles) at the discretion of the investigator.
- •Patients with unresolved toxicities of grade 2 or more from prior anti-cancer therapies excluding alopecia.
- •Untreated or symptomatic central nervous system metastases. Patients with treated brain metastases stable for 3 months are eligible to enroll.
- •Major surgical procedures within 28 days prior to enrolment.
- •Clinically significant cardiovascular diseases that are symptomatic or uncontrolled.
- •Known active infection for human immunodeficiency virus, hepatitis B and C.
- •Pregnant or breast-feeding females.
- •Treatment with any of the following anti-cancer therapies prior to the first dose of study drugs within the stated timeframes
- •Cyclical chemotherapy within a period of time that is shorter than the cycle length used for that treatment. Exception for weekly chemotherapy regimens, where a minimum of 2 week washout from the last dose is required.
- •Biological therapy (e.g., antibodies) within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks, whichever is shorter, prior to starting study drug
- •Continuous or intermittent small molecule therapeutics within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks (whichever is shorter) prior to starting study drug
- •Any other investigational agents within a period of time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤ 4 weeks (whichever is shortest) prior to starting study drug
- •Wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug
- •Previous combination therapy with xeloda and oxaliplatin within 6 months of study treatment.
- •Previous combination therapy with Oxaliplatin, 5-FU and Leucovorin (mFolfox6) within 6 months of study treatment
研究组 & 干预措施
ASLAN001 + CAPOX
Experimental
ASLAN001 + CAPOX: ASLAN001 twice daily in combination with oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 850 mg/m2 orally twice daily on days 1 to 14 every 3 weeks
干预措施: ASLAN001+ CAPOX (Oxaliplatin, capecitabine) (Drug)
ASLAN001 + mFolfox6
Experimental
ASLAN001 + mFolfox6: ASLAN001 twice daily in combination with mFolfox6 (oxaliplatin 85 mg/m2 intravenously on day 1 and 5-FU bolus 400mg/m2 i.v on day 1 and as a continuous infusion 2400mg/ m2 over 46h and leucovorin 400mg/2 i.v on day 1) every 2 weeks
干预措施: ASLAN001 + mFolfox6 (5-FU, leucovorin) (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD) of ASLAN001 when used in combination with Oxaliplatin and Capecitabine (CAPOX) or Oxaliplatin and 5-FU with leucovorin (mFolfox6)
时间窗: one year
次要结局
- Pharmacokinetic parameter Area under the plasma concentration time curve (AUC)(Day 1 and Day 15 of Cycle 1 and Day 1 of Cycle 3)
- Pharmacokinetic parameter Minimum (trough) plasma concentration (Cmin)(Day 1 and Day 15 of Cycle 1 and Day 1 of Cycle 3)
- Efficacy of ASLAN001 when given in combination in CAPOX or mFolfox6 as measured by the objective response rate (ORR)(one year)
- Pharmacokinetic parameter Maximum plasma concentration (Cmax)(Day 1 and Day 15 of Cycle 1 and Day 1 of Cycle 3)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesSquamous Cell Carcinoma of the Head and NeckBreast CancerColorectal CancerNon-small Cell Lung CancerEndometrial CancerGastroEsophageal CancerCastration-resistant Prostate CancerOvarian CancerMelanomaBladder CancerRenal Cell CarcinomaMerkel Cell CarcinomaNCT03629756Arcus Biosciences, Inc.48
已完成
1 期
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced TumorAdvanced TumorsNCT05061628Shanghai Junshi Bioscience Co., Ltd.47
已完成
1 期
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10Advanced Relapsed TumorsRefractory Solid TumorsNCT02482441OncoMed Pharmaceuticals, Inc.50
已完成
1 期
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and LymphomasAdvanced MalignanciesNCT03763149Innovent Biologics (Suzhou) Co. Ltd.20
尚未招募
1 期
AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant TumorsAdvanced Malignant TumorsNCT06691360Akeso87